NCT06200597View on ClinicalTrials.gov

A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects

PHASE1RecruitingINTERVENTIONAL

Enrollment

92

Participants

Timeline

Start Date

December 5, 2023

Primary Completion Date

March 11, 2025

Study Completion Date

March 11, 2025

Conditions

Healthy Volunteers

Interventions

DRUG

LAD603

LAD603 SC injection.

OTHER

Placebo

Matching placebo SC injection.

Trial Locations (1)

66219

RECRUITING

ICON Phase 1 unit Lenexa, Lenexa

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Almirall, S.A.

INDUSTRY